Diamond Hill Capital, a First Eagle Investment Management company, issued its Q1 2026 investor letter for its “Large Cap Strategy”. A copy of the letter is available to download here. The Strategy declined 2.39% (net of fees), trailing the Russell 1000 Value Index’s 2.10%. The performance was positively affected by stock selection in industrials and consumer discretionary, along with an underweight in communication services. While stock selection in information technology, financials, and health care was the largest detractor from relative performance. The war in Iran is creating uncertainty in markets. However, it effectively supported the portfolio’s focus on oil-sensitive exploration and production companies. Technology companies are under pressure in Q1 amid concerns about AI’s potential negative effects on their businesses, but their competitive advantages remain stronger than their current valuations suggest. Despite these challenges, the market is beginning to expand into more attractive opportunities, especially in defensive sectors and cyclicals that do not benefit from AI. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Diamond Hill Capital Large Cap Strategy highlighted Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is a global healthcare company that develops and manufacturers medical devices, diagnostics and nutritional products. On May 22, 2026, Abbott Laboratories (NYSE:ABT) closed at $87.77 per share. One-month return of Abbott Laboratories (NYSE:ABT) was -5.81%, and its shares lost 33.43% over the past 52 weeks. Abbott Laboratories (NYSE:ABT) has a market capitalization of $152.88 billion.
Diamond Hill Capital Large Cap Strategy stated the following regarding Abbott Laboratories (NYSE:ABT) in its Q1 2026 investor letter:
“Shares of diversified health care company Abbott Laboratories (NYSE:ABT) declined following Q4 results and forward guidance that were below expectations, largely due to headwinds in its nutrition business.”
Abbott Laboratories (NYSE:ABT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 71 hedge fund portfolios held Abbott Laboratories (NYSE:ABT) at the end of the fourth quarter, up from 68 in the previous quarter. While we acknowledge the risk and potential of Abbott Laboratories (NYSE:ABT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Abbott Laboratories (NYSE:ABT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Abbott Laboratories (NYSE:ABT) and shared the list of best medical technology stocks to buy. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
